Cigna’s January 2019 Formulary Strategy

As part of our ongoing commitment to provide affordable and quality health care coverage, we regularly review and update our formularies. Our low-net drug cost approach challenges drug manufacturers to rethink traditional pricing by removing certain high-priced, low-value drugs – regardless of incentives or rebates. This proven strategy combined with our effective and integrated utilization management programs, drives lower costs and promotes the use of clinically appropriate alternatives. This approach helped us deliver 12% lower pharmacy cost for clients since 2016¹ and an average $42 PMPY savings to our clients in 2017² while improving the health of our customers.

Starting January 1, 2019, we’ll make formulary changes in drug classes such as ADHD, anticonvulsants and topical acne – and we’re expanding our formularies and reducing cost for certain drugs used for conditions such as HIV, chronic stomach acid (Proton Pump Inhibitors [PPI]) and inflammatory (Crohn’s and ulcerative colitis) digestive conditions.          

Click here to learn more about our July 2018 formulary strategy. 

1. Savings from 2016–2018 Q2 for formularies that use low net drug cost approach, use average client pricing inclusive of both ingredient cost and rebate improvements; excludes global business.
2. Cigna National Book of Business pricing analysis 2017 – for Cigna formularies that use low net drug cost approach.